CEO UPDATE
Bright Green (Nasdaq: BGXX) has announced significant progress in several areas. The company confirmed its first three applications under the EB-5 investment program with Asia Capital Pioneers Group and expects more investors to follow. The first event of this partnership on May 26 featured over 100 potential investors. Bright Green has also submitted DEA 2025 quota requests for producing 22 Schedule I and II controlled substances, aiming to dominate the production of several key substances if approved. Collaborating with CEADL, the company is finalizing preparations to start production by Q1 2025. Additionally, Bright Green is establishing an in-house API and Plant Genetics Research and Medical team to support growth and leverage smart farming and AI technologies. The DEA's potential reclassification of cannabis to Schedule III is seen as beneficial, potentially boosting demand and positioning Bright Green as a major producer in the cannabis industry.
- Confirmed first three applications under EB-5 investment program.
- Over 100 potential investors attended the first EB-5 event.
- Submitted DEA 2025 quota requests for 22 Schedule I and II substances.
- Aiming to handle 70% of marijuana and other key substance production within the DEA program.
- Collaborating with CEADL to finalize facility preparations, aiming for production by Q1 2025.
- Establishing in-house API and Plant Genetics Research and Medical team.
- Potential DEA reclassification of cannabis to Schedule III seen as beneficial.
- Anticipates increased demand for cannabis as an active ingredient by 2025.
- Success contingent on obtaining necessary DEA approvals and quotas.
- Dependence on investor interest and capital inflow for EB-5 program.
- Production start reliant on timely completion of facility upgrades and regulatory clearances.
- Potential risks if fundraising, construction, and approvals do not proceed as planned.
Insights
The recent announcements from Bright Green Corporation highlight several significant developments that could impact investor sentiment and the company's financial performance. Firstly, the progress in their EB-5 investment program shows promise for attracting substantial capital, which is important for funding their ambitious growth plans. With successful initial applications and growing investor interest, this could potentially lead to a strong infusion of
Regarding their DEA quota requests, if approved, Bright Green aims to capture a significant market share in the production of Schedule I and Schedule II substances. This could position them as a leading supplier in a highly regulated and potentially lucrative market. However, investors should be aware of the inherent risks associated with regulatory approvals and the timelines involved. Delays or denials could impact their projected growth and revenue streams.
Additionally, the internal pivot to establish an in-house API and Plant Genetics Research and Medical team suggests a strategic shift towards greater control over their R&D processes. This could enhance their ability to innovate and respond quickly to market demands, but it also means a significant increase in operational costs in the short term.
Overall, while the potential for growth is evident, investors should consider the risks and uncertainties, especially pertaining to regulatory approvals and execution of their expansion plans.
The company's focus on the production of Schedule I and Schedule II controlled substances, including cannabis and psychedelics like mescaline and psilocybin, reflects a growing interest in the medical and therapeutic potential of these substances. The reclassification of cannabis to a Schedule III substance by the DEA could indeed lower regulatory barriers and stigma, potentially leading to increased research and commercial opportunities.
For investors, it's important to note that the medical research and pharmaceutical industries are experiencing a paradigm shift towards exploring the benefits of these substances. Bright Green's strategic positioning and ongoing partnerships could place them at the forefront of this emerging market. However, the success of their commercialization efforts will heavily depend on obtaining the necessary approvals and effectively scaling production.
The in-house R&D initiative could accelerate their innovation cycle, providing a competitive edge in developing new therapies. However, this move also entails taking on additional responsibilities and risks associated with leading cutting-edge research in a tightly regulated sector.
The optimistic outlook presented by Bright Green Corporation is underpinned by several strategic initiatives that align well with current market trends. The growing acceptance and legalization of cannabis and psychedelic substances for medical use are creating new market opportunities. Bright Green's proactive steps, such as their EB-5 investment program and strategic DEA quota requests, are designed to capitalize on these trends.
However, the actual impact on the market and Bright Green’s position will depend on their ability to execute these plans effectively. The company's goal to handle substantial percentages of the DEA's quotas for various substances is ambitious and would require significant operational excellence and compliance with stringent regulatory standards.
For retail investors, the potential upside is substantial if Bright Green can navigate the regulatory landscape and secure the necessary approvals. However, the inherent risks, especially related to regulatory delays and the execution of large-scale production, should also be factored in. An investor should monitor the progress of their quota approvals and any updates on their commercialization timelines closely.
GRANTS, NEW MEXICO, May 30, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX)
Dear BGXX Shareholders,
I’m writing to you today to share an update on several developments for Bright Green Corporation (“Bright Green” or the “Company”) over the past few months. We’ve experienced massive shifts within the industry since the start of 2024 — shifts that have presented exciting growth opportunities for Bright Green.
I’ll begin with an update on the state of our groundbreaking EB-5 investment program in partnership with Asia Capital Pioneers Group (“ACPG”). I’m thrilled to share with you that we have confirmed our first three applications through this partnership and have been informed that more than a dozen additional investors have taken steps to begin the program investment.
To capitalize on this momentum, the team at ACPG just completed the first successful event on the 26th of May. This kicks off a series of events hosted by ACPG and featuring the Company, and the Company’s EB-5 program. With more than 100 potential investors in attendance at the first event, we are optimistic about the immense interest we’re experiencing, particularly as we look forward to future events in Dubai, Singapore and Malaysia. We will be sharing developments from these events on our Regional Center Website.
With our EB-5 program gaining traction, we are moving full steam ahead with our prominent initiative to accelerate our commercialization of Schedule I and Schedule II controlled substances in the U.S., once all necessary approvals are obtained. We have submitted our DEA 2025 quota request for Schedule I and Schedule II substances, meaning that as of today, Bright Green has applied to produce 22 Schedule I and Schedule II controlled substances in total.
| Schedule I | Schedule II |
| Ibogaine | Oxycodone |
| Marijuana Extract | Morphine |
| Marijuana | Morphine Methylbromide |
| Tetrahydrocannabinols | Morphine Methylsulfonate |
| Mescaline | Morphine N Oxide |
| Peyote | Thebaine |
| Psilocybin | Opium, Raw |
| Psilocyn | Opium Extracts |
| Opium Fluid Extracts | |
| Opium (Tincture) | |
| Opium (Powder) | |
| Opium, Granulated | |
| Opium Poppy, Poppy Straw | |
| Poppy Straw Concentrate |
If these quotas and our registration application are approved, we aim to handle
To support this planned growth, we are working closely with the team at CEADL (Controlled Environment Agricultural Design) to establish all of the necessary upgrades for our existing facility, permits, and engineering for our Phase II facility in Grants, New Mexico, and help oversee logistical operations of our planned Schedule I and Schedule II commercialization, and ensure legal compliance and optimal progress. With the support of CEADL, I’m ecstatic to announce we are in the final stages of preparation to begin production at the existing facility. With the current EB-5 push, we aim to deliver initial production by end of the first quarter of 2025. This is very positive news. The plan is to start with the cannabis offerings and trials for our opium plants if we receive all necessary approvals in time.
As things have progressed quickly in our collaboration with CEADL, I want to share an exciting internal pivot that Bright Green has recently undergone. After exploring several potential opportunities for acquisition and partnership, we’ve decided the best path for Bright Green is the establishment of our own in-house API and Plant Genetics Research and Medical team. We feel strongly that this approach will allow us to fully leverage our explorations with Smart Farming and Artificial Intelligence Technology that will better position Bright Green to meet the rapidly-growing demand for Schedule I and Schedule II controlled substances. In addition, bringing our research and development in-house will provide us with more agility as we continue our march through unprecedented territory.
While our Schedule I and Schedule II applications and commercialization remain a focal point, I would like to comment on the recent announcement by the DEA of their initiative to reclassify Cannabis as a Schedule III substance. There have been misconceptions surrounding this rescheduling, so I want to be very clear that we see this as a beneficial opportunity for Bright Green, the cannabis industry, and the world as a whole. We are optimistic that this reclassification will support reducing stigmas and encouraging healthy business flow in the cannabis industry.
As far as what the rescheduling of cannabis means for Bright Green’s business and operations, we expect an increased demand in cannabis as an active ingredient. We believe this will make us the go-to resource best equipped to meet that demand. We anticipate that by 2025 Bright Green will carry
In addition, the continued upside for operators will go well beyond the tax benefits. This reclassification serves as an acknowledgement of state-based medical programs, and we continue to be an advocate for their growth.
Overall, I hope your takeaway from this letter matches my continuous optimism for Bright Green’s forward progress. We are working tirelessly behind the scenes to continue the realization of our established goal: pioneering the “Drugs Made in America” movement to create a reliable domestic API supply chain, and reducing our dependence on foreign drug imports for the betterment of the United States and anyone who calls it home.
We look forward to the future together.
With utmost respect,
Gurvinder Singh
CEO,
Bright Green Corporation
ABOUT BRIGHT GREEN CORPORATION
Bright Green is one of the very few companies selected by the New Mexico Board of Pharmacy for the production, drug manufacturing, marketing and distributing Schedule I-II plant-based drug API including opium, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our approval for cannabis is based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies and more. To learn more, visit www.brightgreen.us
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control, including but not limited to, the inability of the Company to raise funds under the Company’s EB-5 program, receipt of approvals related to our regional center, completion of all required EB-5 submissions by proposed EB-5 participants, receipt of funds by EB-5 participants, outcomes related to the Company’s relationships with ACPG and CEADL, and receipt of necessary Schedule I and II approvals from the DEA. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s most recent Annual Report on Form 10-K, and subsequent Quarterly Reports on Form 10-Q, as each may be amended and supplemented from time to time, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.
Media Contacts:
Interdependence Public Relations
Owen Phillips / Grace Connor
BrightGreen@Interdependence.com
(310) 745-1407
Media Inquiries & Investor Relations Contact
ir@brightgreen.us
FAQ
What are the recent developments for Bright Green (BGXX)?
How is Bright Green's EB-5 investment program performing?
What substances does Bright Green aim to produce under the DEA quota?
What impact will the DEA's potential reclassification of cannabis have on Bright Green?
When does Bright Green plan to start production of controlled substances?
